<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10027317</article-id><article-id pub-id-type="pmc">2362408</article-id><article-id pub-id-type="pii">6690075</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690075</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zee</surname><given-names>J van der</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Holt</surname><given-names>B van der</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rietveld</surname><given-names>P J M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Helle</surname><given-names>P A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wijnmaalen</surname><given-names>A J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Putten</surname><given-names>W L J van</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rhoon</surname><given-names>G C van</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Department of Radiation Oncology, Subdivision of Hyperthermia, University Hospital Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands</aff><aff id="aff2">Department of Statistics, University Hospital Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands</aff><aff id="aff3">Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, The Netherlands</aff><aff id="aff4">Department of Radiation Oncology, University Hospital Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Department of Radiation Oncology, Subdivision of Hyperthermia, University Hospital Rotterdam, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>1999</year></pub-date><volume>79</volume><issue>3-4</issue><fpage>483</fpage><lpage>490</lpage><history><date date-type="received"><day>20</day><month>06</month><year>1997</year></date><date date-type="rev-recd"><day>27</day><month>04</month><year>1998</year></date><date date-type="accepted"><day>15</day><month>06</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Both experimental and clinical research have shown that hyperthermia (HT) gives valuable additional effects when applied in combination with radiotherapy (RT). The purpose of this study was evaluation of results in patients with recurrent breast cancer, treated at the Daniel den Hoed Cancer Center (DHCC) with reirradiation (re-RT; eight fractions of 4 Gy twice weekly) combined with HT. All 134 patients for whom such treatment was planned were included in the analysis. The complete response rate in 119 patients with macroscopic tumour was 71&#x00025;. Including the 15 patients with microscopic disease, the local control rate was 73&#x00025;. The median duration of local control was 32 months, and toxicity was acceptable. The complete response (CR) rate was higher, and the toxicity was less with the later developed 433-MHz HT technique compared with the 2450-MHz technique used initially. With this relatively well-tolerated treatment, palliation by local tumour control of a worthwhile duration is achieved in the majority of patients. The technique used for hyperthermia appeared to influence the achieved results. The value of HT in addition to this re-RT schedule has been confirmed by a prospective randomized trial in a similar patient group. In The Netherlands, this combined treatment is offered as standard to patients with breast cancer recurring in previously irradiated areas. <italic>&#x000a9; 1999 Cancer Research Campaign</italic></p></abstract><kwd-group><kwd>breast cancer</kwd><kwd>reirradiation</kwd><kwd>hyperthermia</kwd><kwd>local tumour control</kwd><kwd>palliation</kwd></kwd-group></article-meta></front></article>